Handing Roche a majority of the equity (2002)

Independence as a banner, or as the money to grow

What marks this decision out is that an independent, founding-family company gave a majority of its control to a foreign owner and still kept the outward form of independence — its listing, its name, its management — written in as conditions. With the domestic market shrinking and the patent on its mainstay Epogin running out, Chugai could not fight the global R&D race alone. Nagayama chose to hand control to Roche and take in exchange a worldwide sales network and an antibody pipeline. Accepting the substance of an acquisition while securing room for self-government by contract is where the design of this combination lies.

Twenty-odd years on, the alliance is generally judged a success. Roche has raised its stake further and now holds roughly 60% of Chugai, yet the listing and the independence of management have held. That outcome, though, rests on Chugai having a technical strength of its own in antibodies — which is what allowed it to keep a relationship of equals with Roche. The Chugai way of combining autonomy with growth under foreign ownership does not transfer as-is to companies without that backing in capability. Which matters more, the banner of independence or the money to grow, is a question still live in a pharmaceutical industry where cross-border restructuring continues.